Cargando…

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer

Treatment-induced AR alterations, including AR alternative splice variants (AR-Vs), have been extensively linked to harboring roles in primary and acquired resistance to conventional and next-generation hormonal therapies in prostate cancer and therefore have gained momentum. Our aim was to uniforml...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isebia, Khrystany T., Lolkema, Martijn P., Jenster, Guido, de Wit, Ronald, Martens, John W. M., van Riet, Job
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053078/ https://www.ncbi.nlm.nih.gov/pubmed/36983083 http://dx.doi.org/10.3390/ijms24066009

Ejemplares similares

Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients
por: Isebia, Khrystany T., et al.
Publicado: (2022)

Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer
por: Dathathri, Eshwari, et al.
Publicado: (2022)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
por: Sieuwerts, Anieta M., et al.
Publicado: (2019)

mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration
por: Snaterse, Gido, et al.
Publicado: (2021)

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning
por: de Jong, Anouk C., et al.
Publicado: (2023)

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
por: van Dessel, Lisanne F., et al.
Publicado: (2019)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
por: Miller, Katie Joanna, et al.
Publicado: (2023)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
por: Cattrini, Carlo, et al.
Publicado: (2019)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
por: Khan, Farhan, et al.
Publicado: (2023)

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
por: Luo, Jun
Publicado: (2016)

Measuring antigen expression of cancer cell lines and circulating tumour cells
por: Mentink, Anouk, et al.
Publicado: (2023)

Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta‐analysis
por: Li, Qinchen, et al.
Publicado: (2021)

Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013)

Crosstalk between KIF15 and AR in castrate-resistant prostate cancers
por: Yang, Hanny, et al.
Publicado: (2022)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
por: Kafka, Mona, et al.
Publicado: (2020)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

RF27 | LBSUN342 Ar-targeted Linked-read Sequencing Reveals Complex Ar Structural Variants In Castration Resistant Prostate Cancer Models
por: Zivanovic, Andrej, et al.
Publicado: (2022)

Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer
por: Vlaeminck-Guillem, Virginie
Publicado: (2020)

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
por: Schlack, Katrin, et al.
Publicado: (2022)

Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
por: Kattan, Michael W., et al.
Publicado: (2020)

Emerging proteins involved in castration-resistant prostate cancer via the AR-dependent and AR-independent pathways (Review)
por: Feng, Kangle, et al.
Publicado: (2023)

The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis
por: Liu, Rui-Ji, et al.
Publicado: (2021)

Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer
por: Ashizawa, Takeshi, et al.
Publicado: (2022)

Kava Components Down-Regulate Expression of AR and AR Splice Variants and Reduce Growth in Patient-Derived Prostate Cancer Xenografts in Mice
por: Li, Xuesen, et al.
Publicado: (2012)

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer()()
por: Qiao, Yuanyuan, et al.
Publicado: (2016)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Li, Qiuhui, et al.
Publicado: (2018)

Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
por: Liu, Yuan, et al.
Publicado: (2021)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells
por: Rana, Manjul, et al.
Publicado: (2021)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
por: Labaf, Maryam, et al.
Publicado: (2022)

Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial
por: Gravestock, Paul, et al.
Publicado: (2023)

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jiaxin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_egkmqldroltud56cfhc278fcr9